Literature DB >> 22341970

Revertant somatic mosaicism by mitotic recombination in dyskeratosis congenita.

Marjolijn C J Jongmans1, Eugene T P Verwiel, Yvonne Heijdra, Tom Vulliamy, Eveline J Kamping, Jayne Y Hehir-Kwa, Ernie M H F Bongers, Rolph Pfundt, Liesbeth van Emst, Frank N van Leeuwen, Koen L I van Gassen, Ad Geurts van Kessel, Inderjeet Dokal, Nicoline Hoogerbrugge, Marjolijn J L Ligtenberg, Roland P Kuiper.   

Abstract

Revertant mosaicism is an infrequently observed phenomenon caused by spontaneous correction of a pathogenic allele. We have observed such reversions caused by mitotic recombination of mutant TERC (telomerase RNA component) alleles in six patients from four families affected by dyskeratosis congenita (DC). DC is a multisystem disorder characterized by mucocutaneous abnormalities, dystrophic nails, bone-marrow failure, lung fibrosis, liver cirrhosis, and cancer. We identified a 4 nt deletion in TERC in a family with an autosomal-dominant form of DC. In two affected brothers without bone-marrow failure, sequence analysis revealed pronounced overrepresentation of the wild-type allele in blood cells, whereas no such skewing was observed in the other tissues tested. These observations suggest that this mosaic pattern might have resulted from somatic reversion of the mutated allele to the normal allele in blood-forming cells. SNP-microarray analysis on blood DNA from the two brothers indeed showed independent events of acquired segmental isodisomy of chromosome 3q, including TERC, indicating that the reversions must have resulted from mitotic recombination events. Subsequently, after developing a highly sensitive method of detecting mosaic homozygosity, we have found four additional cases with a mosaic-reversion pattern in blood cells; these four cases are part of a cohort of 17 individuals with germline TERC mutations. This shows that revertant mosaicism is a recurrent event in DC. This finding has important implications for improving diagnostic testing and understanding the variable phenotype of DC. Copyright Â
© 2012 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22341970      PMCID: PMC3309184          DOI: 10.1016/j.ajhg.2012.01.004

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  33 in total

1.  Dyskeratosis congenita fibroblasts are abnormal and have unbalanced chromosomal rearrangements.

Authors:  I Dokal; J Bungey; P Williamson; D Oscier; J Hows; L Luzzatto
Journal:  Blood       Date:  1992-12-15       Impact factor: 22.113

2.  Fatal diffuse capillaritis after hematopoietic stem-cell transplantation for dyskeratosis congenita despite low-intensity conditioning regimen.

Authors:  P Brazzola; M Duval; J C Fournet; F Gauvin; J H Dalle; J Champagne; M A Champagne
Journal:  Bone Marrow Transplant       Date:  2005-12       Impact factor: 5.483

3.  Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation.

Authors:  Tom J Vulliamy; Anna Marrone; Stuart W Knight; Amanda Walne; Philip J Mason; Inderjeet Dokal
Journal:  Blood       Date:  2005-12-06       Impact factor: 22.113

Review 4.  Replication and protection of telomeres.

Authors:  Ramiro E Verdun; Jan Karlseder
Journal:  Nature       Date:  2007-06-21       Impact factor: 49.962

5.  Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure.

Authors:  Tom J Vulliamy; Amanda Walne; Aroon Baskaradas; Philip J Mason; Anna Marrone; Inderjeet Dokal
Journal:  Blood Cells Mol Dis       Date:  2005 May-Jun       Impact factor: 3.039

6.  Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita.

Authors:  Mary Armanios; Jiunn-Liang Chen; Yen-Pei Christy Chang; Robert A Brodsky; Anita Hawkins; Constance A Griffin; James R Eshleman; Alan R Cohen; Aravinda Chakravarti; Ada Hamosh; Carol W Greider
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-24       Impact factor: 11.205

Review 7.  Telomere length regulation.

Authors:  C W Greider
Journal:  Annu Rev Biochem       Date:  1996       Impact factor: 23.643

8.  Telomerase mutations in families with idiopathic pulmonary fibrosis.

Authors:  Mary Y Armanios; Julian J-L Chen; Joy D Cogan; Jonathan K Alder; Roxann G Ingersoll; Cheryl Markin; William E Lawson; Mingyi Xie; Irma Vulto; John A Phillips; Peter M Lansdorp; Carol W Greider; James E Loyd
Journal:  N Engl J Med       Date:  2007-03-29       Impact factor: 91.245

9.  Adult-onset pulmonary fibrosis caused by mutations in telomerase.

Authors:  Kalliopi D Tsakiri; Jennifer T Cronkhite; Phillip J Kuan; Chao Xing; Ganesh Raghu; Jonathan C Weissler; Randall L Rosenblatt; Jerry W Shay; Christine Kim Garcia
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-25       Impact factor: 11.205

10.  Spontaneous functional correction of homozygous fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism.

Authors:  Q Waisfisz; N V Morgan; M Savino; J P de Winter; C G van Berkel; M E Hoatlin; L Ianzano; R A Gibson; F Arwert; A Savoia; C G Mathew; J C Pronk; H Joenje
Journal:  Nat Genet       Date:  1999-08       Impact factor: 38.330

View more
  51 in total

1.  De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly.

Authors:  Jeong Ho Lee; My Huynh; Jennifer L Silhavy; Sangwoo Kim; Tracy Dixon-Salazar; Andrew Heiberg; Eric Scott; Vineet Bafna; Kiley J Hill; Adrienne Collazo; Vincent Funari; Carsten Russ; Stacey B Gabriel; Gary W Mathern; Joseph G Gleeson
Journal:  Nat Genet       Date:  2012-06-24       Impact factor: 38.330

2.  Small-Molecule PAPD5 Inhibitors Restore Telomerase Activity in Patient Stem Cells.

Authors:  Neha Nagpal; Jianing Wang; Jing Zeng; Emily Lo; Diane H Moon; Kevin Luk; Roman O Braun; Lauri M Burroughs; Sioban B Keel; Christopher Reilly; R Coleman Lindsley; Scot A Wolfe; Albert K Tai; Patrick Cahan; Daniel E Bauer; Yick W Fong; Suneet Agarwal
Journal:  Cell Stem Cell       Date:  2020-04-21       Impact factor: 24.633

3.  Somatic mutations in telomerase promoter counterbalance germline loss-of-function mutations.

Authors:  Lindley Maryoung; Yangbo Yue; Ashley Young; Chad A Newton; Cindy Barba; Nicolai S C van Oers; Richard C Wang; Christine Kim Garcia
Journal:  J Clin Invest       Date:  2017-02-13       Impact factor: 14.808

4.  Somatic recombination in adult tissues: What is there to learn?

Authors:  Katarzyna Siudeja; Allison J Bardin
Journal:  Fly (Austin)       Date:  2016-11-11       Impact factor: 2.160

5.  Somatic reversion events point towards RPL4 as a novel disease gene in a condition resembling Diamond-Blackfan anemia.

Authors:  Marjolijn C J Jongmans; Illja J Diets; Paola Quarello; Emanuela Garelli; Roland P Kuiper; Rolph Pfundt
Journal:  Haematologica       Date:  2018-09-13       Impact factor: 9.941

Review 6.  Genetic predisposition to MDS: clinical features and clonal evolution.

Authors:  Alyssa L Kennedy; Akiko Shimamura
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

7.  Poly(A)-specific ribonuclease (PARN) mediates 3'-end maturation of the telomerase RNA component.

Authors:  Diane H Moon; Matthew Segal; Baris Boyraz; Eva Guinan; Inga Hofmann; Patrick Cahan; Albert K Tai; Suneet Agarwal
Journal:  Nat Genet       Date:  2015-10-19       Impact factor: 38.330

8.  Diagnosis of Fanconi anemia by diepoxybutane analysis.

Authors:  Arleen D Auerbach
Journal:  Curr Protoc Hum Genet       Date:  2015-04-01

Review 9.  Cancer and myeloid clonal evolution in the short telomere syndromes.

Authors:  Kristen E Schratz; Mary Armanios
Journal:  Curr Opin Genet Dev       Date:  2020-04-07       Impact factor: 5.578

10.  Clonal hematopoiesis in patients with dyskeratosis congenita.

Authors:  Nieves Perdigones; Juan C Perin; Irene Schiano; Peter Nicholas; Jaclyn A Biegel; Philip J Mason; Daria V Babushok; Monica Bessler
Journal:  Am J Hematol       Date:  2016-10-21       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.